With BoD Resolution no. 15 of 26 April 2023, the Italian Medicines Agency admits the indication for reimbursement of the combination Emtricitabine/Tenofovir Disoproxil for "Pre-exposure prophylaxis (PrEP) and in order to reduce the risk of sexually transmitted HIV-1 infection in adults and adolescents at high risk". It is an additional prevention tool for […]
read more